ABVX News

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Focus on French HealthTech’s ecosystem : Panorama France HealthTech 2026 ‘s review: a mature, innovative and resilient sector facing a more demanding environment

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Truffle Capital Unveils the First Edition of the Truffle MedTech 10

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Provides 2026 Corporate Outlook